UroToday
VerifiedOnline/Digital
UroToday publishes evidence-based clinical content that is organized across the site by disease, treatments and guidelines. This educational platform offers written articles, video lectures or discussions and emerging data presented at conferences. The content across the site is developed, organized and presented by leaders across the urology field. Further, UroToday offers a portal providing access to enrolling clinical trials. The Centers of Excellence (CoE) provide state of the art lectures, original articles and research organized by disease and condition and focused on what is known about treatments or what is emerging in clinical care. Each CoE is led by a clinician-editor and invited faculty. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesProsTIC 2026 Global Theranostics Conference
Viewing 1-11 of 11 articles Login to update email address, newsletter preferences and use bookmarks. Email Password Forgot Password? Sign Up Free
ProsTIC26: The Use of External Beam Radiotherapy During Treatment With 177Lu-PSMA-617 for mCRPC
(UroToday.com) The 2026 ProsTIC annual meeting featured a best selected posters session and a presentation by Dr. Sohyun Kim discussing the use of external beam radiotherapy during treatment with 177Lu-PSMA-617 for metastatic castration resistant prostate cancer (mCRPC). Increasingly, 177Lu-PSMA-617 is used for patients with mCRPC, while many of these patients may also require palliative external beam radiotherapy during the course of their disease.
ProsTIC26: PSMA Imaging and Theranostics in China Today
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA in Asia and Australia session and a presentation by Dr. Yao Zhu discussing PSMA imaging and theranostics in China today. Dr. Zhu organized his presentation around three themes: prostate cancer and theranostics in China today, the increasingly competitive radioligand therapy development landscape, and China’s transition from fast follower to new tracers.
ProsTIC26: PETomics: Integrating PET Imaging and ctDNA Genomics via Deep Learning to Predict Response to 177Lu-PSMA‑617 in mCRPC Patients
(UroToday.com) The 2026 ProsTIC annual meeting featured a best selected posters session and a presentation by Dr. Mevan Ekanayake discussing PETomics, integration of PET imaging and ctDNA genomics via deep learning to predict response to 177Lu-PSMA‑617 in mCRPC patients. The premise of PETomics is that the different sources of information available before 177Lu-PSMA‑617 therapy may provide complementary rather than redundant information.
ProsTIC26: PSMASegmentator: Open-Source, AI-Based Software for PSMA PET/CT Automatic Segmentation and Prognostic Biomarker Extraction
(UroToday.com) The 2026 ProsTIC annual meeting featured a best selected posters session and a presentation by Joel Noble discussing PSMASegmentator, an open-source, AI-based software for PSMA PET/CT automatic segmentation and prognostic biomarker extraction. PSMA PET/CT contains substantially more quantitative information than simply the presence or absence of metastatic disease.
ProsTIC26: Neoadjuvant 177Lu-PSMA-I&T Combined with Moderately Hypofractionated Radiotherapy in High-Risk Localized Prostate Cancer: A Multicentric Phase I TiTE-CRM Study (LU-EBRT)
(UroToday.com) The 2026 ProsTIC annual meeting featured a best selected posters session and a presentation by Dr. Genevieve Loos discussing a phase 1 study of neoadjuvant 177Lu-PSMA-I&T combined with moderately hypofractionated radiotherapy in high-risk localized prostate cancer. LuTectomy [1] previously demonstrated safety and feasibility for giving high risk localized prostate cancer patients 1-2 doses of 177Lu-PSMA-617 prior to radical prostatectomy.
ProsTIC26: Prospective Evaluation of Amino Acid Co-Infusion for Renal Dose Reduction During 177Lu-PSMA-I&T Therapy: Interim Results from the RENOGUARD Trial
(UroToday.com) The 2026 ProsTIC annual meeting featured a best selected posters session and a presentation by Dr. Zeyad Al-Ogaili discussing interim results from the RENOGUARD trial, a prospective evaluation of amino acid co-infusion for renal dose reduction during 177Lu-PSMA-I&T therapy. As the use of PSMA-targeted radioligand therapy continues to expand, cumulative radiation exposure to normal organs, particularly the kidneys, remains an important consideration.
Long-term Prediction of Metastatic Recurrence in Patients Candidate to Radical Prostatectomy Using MRI and Targeted Biopsy: Insights into Tumor Zonal Origin.
Prostate cancer recurrence after radical prostatectomy (RP) is primarily driven by tumor aggressiveness, but accurate long-term prediction remains challenging. We evaluated long-term oncological outcomes using magnetic resonance imaging (MRI) and targeted biopsy data in 646 patients treated with RP between 2009 and 2018, and the median follow-up for survivors was 8. 3 yr. The primary end point was metastatic recurrence and the secondary end point was biochemical recurrence (BCR).
Dietary Fat Intake and Mortality Among Patients With Nonmetastatic Prostate Cancer.
There are 3.5 million prostate cancer survivors in the US, with a need for evidence-based lifestyle recommendations that improve survivorship. To assess whether consumption of specific dietary fats after diagnosis is associated with long-term survival among patients with nonmetastatic prostate cancer.
Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral.
RADICAL PC-2 (RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients) was a pragmatic randomized controlled trial that tested whether routine referral to a cardiologist or an internist for cardiovascular (CV) risk-factor and lifestyle modification improves outcomes in patients with prostate cancer or receiving androgen-deprivation therapy.